Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The employee’s options vest over four years, subject to continued service, and carry a 10-year term.

Rhea-AI Summary

Compass Therapeutics (CMPX) granted a new employee stock options covering 200,000 common shares as an inducement to employment under its 2025 Inducement Plan.

The exercise price is $0.86 per share, matching the October 13, 2026 closing share price. The options have a 10-year term and vest over four years: 25% on the grant’s first anniversary and the remaining 75% in 36 substantially equal monthly installments, subject to continued service. The grant complies with Nasdaq Listing Rule 5635(c)(4), sits outside the 2020 Stock Option and Incentive Plan, and is subject to the 2025 Inducement Plan and applicable award agreement.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 200,000 common shares at $0.86 per share create potential dilution upon exercise.

Key Figures

Options granted: 200,000 shares Exercise price: $0.86 per share Option term: 10 years +3 more

Options granted

200,000 shares

Inducement grant to a new employee

Exercise price

$0.86 per share

Equal to the October 13 closing price

Option term

10 years

Inducement grant

Vesting period

4 years

Subject to continued service

Initial vesting

25%

On the one-year anniversary of the grant date

Remaining vesting

75% over 36 monthly installments

Substantially equal installments after the one-year anniversary

Key Terms

non-qualified stock options, nasdaq listing rule 5635(c)(4)

2 terms

non-qualified stock options financial

"non-qualified stock options to purchase 200,000 shares of common stock"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grant consists of non-qualified stock options to purchase 200,000 shares of common stock at an exercise price of $0.86 per share, which is equal to the closing price of the Company’s common stock on October 13, 2026. The options have a 10-year term and vest over four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remaining 75% vesting in 36 substantially equal monthly installments thereafter, subject to each respective employee’s continued service with the Company. The inducement grant was outside of the Company’s 2020 Stock Option and Incentive Plan and is subject to the Company’s 2025 Inducement Plan and the applicable award agreement.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company dedicated to transforming the standard of care for patients with cancer through the discovery and development of innovative antibody-based therapeutics. The company leverages deep expertise in tumor biology and proprietary antibody engineering technologies to develop differentiated therapies that target the intersection of angiogenesis, immune activation, and tumor-driven immunosuppression. Compass has a robust pipeline of novel product candidates designed to address significant unmet needs and improve outcomes for patients with cancer. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the terms of Compass Therapeutics’ employee inducement options?

The grant covers 200,000 common shares at an exercise price of $0.86 per share, equal to the October 13, 2026 closing share price. The options have a 10-year term.

How do Compass Therapeutics’ inducement options vest?

The options vest over four years, subject to continued service with the company. The first 25% vests on the one-year anniversary of the grant date, and the remaining 75% vests in 36 substantially equal monthly installments thereafter.